Cantor Fitzgerald analyst Joseph France maintained a Buy rating on Genesis Healthcare (NYSE: GEN) today and set a price target of $7. The company’s shares opened today at $1.52.
France observed:
“We rate GEN $7 price target. We believe that the company is well- positioned to capitalize on the growing post-acute-care market and that its stronger and still-improving capital structure and the further development of value-based reimbursement initiatives will drive faster earnings growth. We expect profitability to improve as the company becomes a more-important player in the post-acute-care market by lowering unanticipated hospital readmissions. $7 price target is based on a blend of DCF and comparable-company analysis.”
According to TipRanks.com, France is a 5-star analyst with an average return of 11.6% and a 61.8% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and Envision Healthcare.
Genesis Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $7.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.86 and a one-year low of $0.60. Currently, Genesis Healthcare has an average volume of 941.7K.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genesis Healthcare, Inc. is a holding company, which engages in the provision of inpatient services through skilled nursing and assisted and senior living communites. It also offers rehabilitation and respiratory therapy services. It operates through the following segments: Inpatient, Rehabilitation Therapy, and Other Services.
